Comparison of midazolam and simvastatin as cytochrome P450 3A probes

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 4, 2006, Pages 350-361

  Chung, Ellen ^a   Nafziger, Anne N ^a   Kazierad, David J ^a   Bertino Jr , Joseph S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; KETOCONAZOLE; MIDAZOLAM; RIFAMPICIN; SIMVASTATIN; DIAGNOSTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; INTRAVENOUS ANESTHETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GEOMETRY; HUMAN; MALE; MOLECULAR PROBE; NORMAL HUMAN; PRIORITY JOURNAL; VALIDATION STUDY; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, INTRAVENOUS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MIDAZOLAM; SIMVASTATIN;

EID: 33646100099     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.11.016     Document Type: Article

References (47)

1. Rogers J.F., Nafziger A.N., and Bertino Jr. J.S. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113 (2002) 746-750
2. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., et al. The conduct of in vitro and in vivo drug-drug interaction studies. a PhRMA perspective. J Clin Pharmacol 43 (2003) 443-469
3. Watkins P.B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4 (1994) 171-184
4. Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., and Wrighton S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47 (1994) 1643-1653
5. Kronbach T., Mathys D., Umeno M., Gonzalez F.J., and Meyer U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36 (1989) 89-96
6. Backman J.T., Olkkola K.T., and Neuvonen P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59 (1996) 7-13
7. Gorski J.C., Vannaprasaht S., Hamman M.A., Ambrosius W.T., Bruce M.A., Haehner-Daniels B., et al. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74 (2003) 275-287
8. Olkkola K.T., Backman J.T., and Neuvonen P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55 (1994) 481-485
9. Tsunoda S.M., Velez R.L., von Moltke L.L., and Greenblatt D.J. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo. effect of ketoconazole. Clin Pharmacol Ther 66 (1999) 461-471
10. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16 (1999) 408-414
11. Gorski J.C., Jones D.R., Haehner-Daniels B.D., Hamman M.A., O'Mara Jr. E.M., and Hall S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64 (1998) 133-143
12. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59 (1996) 491-502
13. Streetman D.S., Bertino J.S., and Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults. a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10 (2000) 187-216
14. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Hartwell P.S., et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271 (1994) 549-556
15. Olkkola K.T., Aranko K., Luurila H., Hiller A., Saarnivaara L., Himberg J.J., and Neuvonen P.J. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53 (1993) 298-305
16. Backman J.T., Olkkola K.T., Ojala M., Laaksovirta H., and Neuvonen P.J. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 37 (1996) 253-257
17. Pentikäinen P.J., Välisalmi L., Himberg J.J., and Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29 (1989) 272-277
18. Dept. of Health and Human Services (US), Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies-study design, data analysis, and recommendations for dosing and labeling (1999), Center for Drug Evaluation and Research, Rockville (MD)
19. Prueksaritanont T., Gorham L.M., Ma B., Liu L., Yu X., Zhao J.J., et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450S. Drug Metab Dispos 25 (1997) 1191-1199
20. Prueksaritanont T., Ma B., and Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56 (2003) 120-124
21. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., and Neuvonen P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68 (2000) 592-597
22. Neuvonen P.J., Kantola T., and Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63 (1998) 332-341
23. Gruer P.J., Vega J.M., Mercuri M.F., Dobrinska M.R., and Tobert J.A. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 84 (1999) 811-815
24. Rogers J.F., Morrison A.L., Nafziger A.N., Jones C.L., Rocci Jr. M.L., and Bertino Jr. J.S. Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics. Clin Pharmacol Ther 72 (2002) 711-717
25. Kashuba A.D., Bertino Jr. J.S., Rocci Jr. M.L., Kulway R.W., Beck D.J., and Nafziger A.N. Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam. Clin Pharmacol Ther 64 (1998) 269-277
26. Goldstein J.A. Clinical relevance of genetic polymorphisms in human CYP2C subfamily. Br J Clin Pharmacol 52 (2001) 349-355
27. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes. studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299 (2001) 849-857
28. Ong C.E., Coulter S., Birkett D.J., Bhasker R., and Miners J.O. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50 (2000) 573-580
29. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., et al. Glucuronidation of statins in animals and humans. a novel mechanism of statin lactonization. Drug Metab Dispos 30 (2002) 505-512
30. Hochman J.H., Pudvah N., Qiu J., Yamazaki M., Tang C., Lin J.H., et al. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21 (2004) 1686-1691
31. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274 (1999) 37161-37168
32. Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 (2001) 597-607
33. Shim C.K., and Hong J.S. Inter- and intrasubject variations of ranitidine pharmacokinetics after oral administration to normal male subjects. J Pharm Sci 78 (1989) 990-994
34. van Hecken A.M., Tjandramaga T.B., Mullie A., Verbesselt R., and de Schepper P.J. Ranitidine. single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol 14 (1982) 195-200
35. Roberts M.S., Magnusson B.M., Burczynski F.J., and Weiss M. Enterohepatic circulation physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41 (2002) 751-790
36. Vickers S., Duncan C.A., Vyas K.P., Kari P.H., Arison B., Prakash S.R., et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 18 (1990) 476-483
37. Vickers S., Duncan C.A., Chen I.W., Rosegay A., and Duggan D.E. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 18 (1990) 138-145
38. Reinoso R.F., Sanchez Navarro A., Garcia M.J., and Prous J.R. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 24 (2002) 593-613
39. Hiller A., Nguyen N., Strassburg C.P., Li Q., Jainta H., Pechstein B., et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 27 (1999) 605-612
40. Thummel K.E., Shen D.D., Podoll T.D., Kunze K.L., Trager W.F., Bacchi C.E., et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271 (1994) 557-566
41. Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism. prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24 (1996) 475-490
42. Lin Y.S., Dowling A.L., Quigley S.D., Farin F.M., Zhang J., Lamba J., et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (2002) 162-172
43. Zhu B., Liu Z.Q., Chen G.L., Chen X.P., Ou-Yang D.S., Wang L.S., et al. The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55 (2003) 264-269
44. Wolbold R., Klein K., Burk O., Nussler A.K., Neuhaus P., Eichelbaum M., et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38 (2003) 978-988
45. Greenblatt D.J., Abernethy D.R., Locniskar A., Harmatz J.S., Limjuco R.A., and Shader R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61 (1984) 27-35
46. Cheng H., Rogers J.D., Sweany A.E., Dobrinska M.R., Stein E.A., Tate A.C., et al. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 9 (1992) 1629-1633
47. Cummins C.L., Wu C.Y., and Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72 (2002) 474-489